Monday, October 10, 1994
The travails of the D. Blech companies aside, share price pressures in the sector in
recent weeks more likely have resulted from the unwinding of Oppenheimer's Global Bio-Tech
Fund, which has halved its biotech position from about $150 million since early July.
Following Oppenheimer's decision in July to avoid the volatility associated with